Vaxxinity (VAXX) 10-Q 2023 Q3 Quarterly report

1

Exhibit 32.1

CERTIFICATIONSOF PRINCIPAL EXECUTIVEOFFICER AND PRINCIPALFINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Vaxxinity,Inc. (the “Company”) on Form 10-Q for the quarter ended

September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the

undersigned hereby certify, pursuantto 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley

Act of 2002, that, to the best of their knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act

of 1934, as amended; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition

and results of operations of the Company.

Date: November 8, 2023By:/s/ Mei Mei Hu

Mei Mei Hu

President and Chief Executive Officer

(Principal Executive Officer)

Date: November 8, 2023By:/s/ Jason Pesile

Jason Pesile

Senior Vice President, Finance and Accounting

(Principal Financial and Accounting Officer)